Introduction. Protamine has intrinsic anticoagulant properties and protamine dosing based on a fixed dosing ratio to heparin might overdose protamine impairing patient hemostasis. This study compared hemostasis of fixed ratio protamine dosing to protamine dosing based on a novel computerized pharmacokinetic (PK) model of heparin.Methods. This case-control study included 109 patients undergoing elective cardiac surgery with CPB. In 56 patients protamine was dosed in a fixed ratio, while 63 patients received protamine based on the PK-model. Study parameters included delta activated clotting time (ΔACT ¼ ACT after protamine minus preoperative ACT), aPTT, rotational thromboelastometry (INTEM and HEPTEM), blood loss and blood transfusion. Data was analysed by Student's T-test or Mann Witney test.Results. There was no difference in the amount of heparin administrated (414 Ϯ 107 mg (fixed ratio group) vs. 403 Ϯ 90 mg (PK-group); n.s.), whereas protamine dosing was considerably different with a protamine:heparin-ratio of 1.1 Ϯ 0.3 for the fixed dosing ratio and 0.5 Ϯ 0.1 for the PK-group, po0.001. The ΔACT values were not different (þ17 Ϯ 77 s for the fixed ratio group and þ6 Ϯ 15 s for the PK-dosed group). Postoperative aPTT values were similar (42 Ϯ 13 s vs. 43 Ϯ 5 s; n.s.). Thromboelastometric data were prolonged in the routine practice group compared to the PK group, INTEM clotting time (CT) 250 Ϯ 76 s vs. 198 Ϯ 32 s and HEPTEM CT 275 Ϯ 105 vs. 198 Ϯ 32 s (both Po0.001). Median packed red blood cell transfusion ((0 (0-2) vs. 0(0-0)), fresh frozen plasma transfusion ((1 (0-2) vs. 0 (0-0)) and platelet concentrate transfusion (0 (0-1) vs. 0 (0-0)) were different between the fixed ratio and PK group, respectively (all Po0.001). Although postoperative hemostasis differed 24-hour postoperative blood loss did not differ between the fixed ratio and PK group, (389 (293-548) ml vs. 340 (243-525) ml; n.s.). Conclusion. Patient-tailored protamine dosing based on a pharmacokinetic model resulted in a significant reduction of protamine dosing with better hemostasis and fewer blood product transfusion when compared to fixed ratio protamine dosing.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.